 | Up a level |
Geraghty, Rob; Wilson, Ian; Olinger, Eric; Cook, Paul; Troup, Susan; Kennedy, David; Rogers, Alistair; Somani, Bhaskar K; Dhayat, Nasser; Fuster, Daniel; Sayer, John (2023). Routine Urinary Biochemistry Does Not Accurately Predict Stone Type Nor Recurrence in Kidney Stone Formers: A Multi-Centre, Multi-Model, Externally Validated Machine-Learning Study. Journal of endourology, 37(12), pp. 1295-1304. Mary Ann Liebert 10.1089/end.2023.0451
Ferreira, Antonio; Schönenberger, Katja; Potoczna, Natascha; Vogt, Andreas; Gerber, Philipp; Zehetner, Jörg; Giachino, Daniel; Nett, Philipp; Gawinecka, Joanna; Cossu, Luca; Fuster, Daniel; Dalla Man, Chiara; Facchinetti, Andrea; Melmer, Andreas; Nakas, Christos T; Hepprich, Matthias; Donath, Marc; Herzig, David; Bally, Lia (2023). Randomized, double-blind, placebo-controlled crossover trial of once daily empagliflozin 25 mg for the treatment of postprandial hypoglycaemia after Roux-en-Y gastric bypass. Diabetes technology & therapeutics, 25(7), pp. 467-475. Mary Ann Liebert 10.1089/dia.2023.0036
Bonny, Olivier; Fuster, Daniel; Seeger, Harald; Ernandez, Thomas; Buchkremer, Florian; Wuerzner, Gregoire; Dhayat, Nasser; Ritter, Alexander; Stoermann, Catherine; Segerer, Stephan; Häusermann, Tanja; Pasch, Andreas; Kim, Minjeong; Mayr, Michael; Krapf, Reto; Roth, Beat; Bochud, Murielle; Mohebbi, Nilufar; Wagner, Carsten A. (2023). The Swiss Kidney Stone Cohort (SKSC), a longitudinal, multi-centric, observational cohort to study course and causes of kidney stone disease in Switzerland. Kidney and blood pressure research, 48(1), pp. 194-201. Karger 10.1159/000529094
Schietzel, Simeon; Bally, Lia; Cereghetti, Grazia; Faller, Nicolas; Moor, Matthias B; Vogt, Bruno; Rintelen, Felix; Trelle, S; Fuster, Daniel (2022). Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial. BMJ open, 12(3), e059073. BMJ Publishing Group 10.1136/bmjopen-2021-059073
Bargagli, Matteo; Ferraro, Pietro Manuel; Dhayat, Nasser; Anderegg, Manuel; Fuster, Daniel (2021). Effect of Tolvaptan treatment on acid-base homeostasis in ADPKD patients. Kidney international reports, 6(6), p. 1749. Elsevier 10.1016/j.ekir.2021.04.012
Wiegand, Anna; Fischer, Gioia; Seeger, Harald; Fuster, Daniel; Dhayat, Nasser; Bonny, Olivier; Ernandez, Thomas; Kim, Min-Jeong; Wagner, Carsten A; Mohebbi, Nilufar (2019). Impact of potassium citrate on urinary risk profile, glucose and lipid metabolism of kidney stone formers in Switzerland. Clinical kidney journal, 13(6), pp. 1037-1048. Oxford University Press 10.1093/ckj/sfz098
Fuster, Daniel; Tsui, Judith I; Cheng, Debbie M; Quinn, Emily K; Bridden, Carly; Nunes, David; Libman, Howard; Saitz, Richard; Samet, Jeffrey H (2013). Impact of Lifetime Alcohol Use on Liver Fibrosis in a Population of HIV-Infected Patients With and Without Hepatitis C Coinfection. Alcoholism: clinical and experimental research, 37(9), pp. 1527-1535. Oxford: Wiley-Blackwell 10.1111/acer.12129
Muga, Roberto; Sanvisens, Arantza; Fuster, Daniel; Tor, Jordi; Martínez, Elisenda; Pérez-Hoyos, Santiago; Muñoz, Alvaro (2012). Unhealthy alcohol use, HIV infection and risk of liver fibrosis in drug users with hepatitis C. PLoS ONE, 7(10), e46810. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0046810
Fuster, Daniel; Tor, Jordi; Rey-Joly, Celestino; Muga, Robert (2012). [Pathogenic interactions between alcohol and hepatitis C]. Medicina clínica, 138(14), pp. 627-32. Barcelona: Elsevier Doyma 10.1016/j.medcli.2011.04.019
